Literature DB >> 32737247

Preclinical Development of 18F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis.

Hazem Ahmed1, Rahel Wallimann1, Ahmed Haider1, Vahid Hosseini2, Stefan Gruber1, Marvin Robledo1, Thi A N Nguyen1, Adrienne Müller Herde1, Irina Iten1, Claudia Keller1, Viola Vogel2, Roger Schibli1,3, Bernhard Wünsch4, Linjing Mu1,3, Simon M Ametamey5.   

Abstract

As part of our continuous efforts to develop a suitable 18F-labeled PET radioligand with improved characteristics for imaging the N-methyl-d-aspartate receptors (NMDARs) subtype 2B (GluN1/2B), we investigated in the current work ortho-fluorinated (OF) and meta-fluorinated (MF) analogs of 18F-para-fluorinated (PF)-NB1, a 3-benzazepine-based radiofluorinated probe.
Methods: OF-NB1 and MF-NB1 were prepared using a multistep synthesis, and their binding affinities toward GluN2B subunits and selectivity over σ1 receptors (σ1Rs) were determined via competitive binding assays. 18F-OF-NB1 was synthesized via copper-mediated radiofluorination and was evaluated in Wistar rats by in vitro autoradiography, PET imaging, ex vivo biodistribution, metabolite experiments, and receptor occupancy studies using CP-101,606, an established GluN2B antagonist. To determine in vivo selectivity, 18F-OF-NB1 was validated in wild-type and σ1R knock-out mice. Translational relevance was assessed in autoradiographic studies using postmortem human brain tissues from healthy individuals and ALS patients, the results of which were corroborated by immunohistochemistry.
Results: The binding affinity values for OF-NB1 and MF-NB1 toward the GluN2B subunits were 10.4 ± 4.7 and 590 ± 36 nM, respectively. For σ1R binding, OF-NB1 and MF-NB1 exhibited inhibition constants of 410 and 2,700 nM, respectively. OF-NB1, which outperformed MF-NB1, was radiolabeled with 18F to afford 18F-OF-NB1 in more than 95% radiochemical purity and molar activities of 192 ± 33 GBq/μmol. In autoradiography experiments, 18F-OF-NB1 displayed a heterogeneous and specific binding in GluN2B subunit-rich brain regions such as the cortex, striatum, hypothalamus, and hippocampus. PET imaging studies in Wistar rats showed a similar heterogeneous uptake, and no brain radiometabolites were detected. A dose-dependent blocking effect was observed with CP-101,606 (0.5-15 mg/kg) and resulted in a 50% receptor occupancy of 8.1 μmol/kg. Postmortem autoradiography results revealed lower expression of the GluN2B subunits in ALS brain tissue sections than in healthy controls, in line with immunohistochemistry results.
Conclusion: 18F-OF-NB1 is a highly promising PET probe for imaging the GluN2B subunits of the N-methyl-d-aspartate receptor. It possesses utility for receptor occupancy studies and has potential for PET imaging studies in ALS patients and possibly other brain disorders.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  GluN2B-subunit; NMDA; PET; amyotrophic lateral sclerosis (ALS); receptor occupancy

Year:  2020        PMID: 32737247     DOI: 10.2967/jnumed.120.246785

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

1.  Comparison of three novel radiotracers for GluN2B-containing NMDA receptors in non-human primates: (R)-[11C]NR2B-Me, (R)-[18F]of-Me-NB1, and (S)-[18F]of-NB1.

Authors:  Kelly Smart; Ming-Qiang Zheng; Hazem Ahmed; Hanyi Fang; Yuping Xu; Lisheng Cai; Daniel Holden; Michael Kapinos; Ahmed Haider; Zachary Felchner; Jim R Ropchan; Gilles Tamagnan; Robert B Innis; Victor W Pike; Simon M Ametamey; Yiyun Huang; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2022-02-25       Impact factor: 6.960

2.  First-in-Humans Brain PET Imaging of the GluN2B-Containing N-methyl-d-aspartate Receptor with (R)-11C-Me-NB1.

Authors:  Lucas Rischka; Chrysoula Vraka; Verena Pichler; Sazan Rasul; Lukas Nics; Gregor Gryglewski; Patricia Handschuh; Matej Murgaš; Godber M Godbersen; Leo R Silberbauer; Jakob Unterholzner; Christoph Wotawa; Ahmed Haider; Hazem Ahmed; Roger Schibli; Thomas Mindt; Markus Mitterhauser; Wolfgang Wadsak; Andreas Hahn; Rupert Lanzenberger; Marcus Hacker; Simon M Ametamey
Journal:  J Nucl Med       Date:  2021-10-07       Impact factor: 11.082

3.  Development and Validation of [3H]OF-NB1 for Preclinical Assessment of GluN1/2B Candidate Drugs.

Authors:  Hazem Ahmed; Livio Gisler; Nehal H Elghazawy; Claudia Keller; Wolfgang Sippl; Steven H Liang; Ahmed Haider; Simon M Ametamey
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-02

Review 4.  A Review of Molecular Imaging of Glutamate Receptors.

Authors:  Jong-Hoon Kim; János Marton; Simon Mensah Ametamey; Paul Cumming
Journal:  Molecules       Date:  2020-10-16       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.